2nd ALS Drug Development Summit
Evvnt Promotion / evvnt
Archiv
16.05.2023 - 18.05.2023 Hilton Boston Logan Airport, One Hotel Drive, 02128 Boston, Massachusetts, USA
9:00 am - 4:30 pm
Kongressthemen
Following the approval of Amylyx's Relyvrio in the US and Canada and further FDA decisions on the horizon in 2023, the ALS drug development landscape is gaining momentum and positivity. With booming pharma investment and new biotechs entering the field, there are still crucial translational challenges to address to bridge the gap and see clinical success for the wider ALS patient population.
Following the approval of Amylyx's Relyvrio in the US and Canada and further FDA decisions on the horizon in 2023, the ALS drug development landscape is gaining momentum and positivity. With booming pharma investment and new biotechs entering the field, there are still crucial translational challenges to address to bridge the gap and see clinical success for the wider ALS patient population.
Kongressorganizer (PCO)
Hanson Wade
Hanson Wade
Anmerkungen
URL:
Brochure: https://go.evvnt.com/1485150-3?pid=4832
Speakers: Alain Moussy, Co-Founder and Chief Executive Officer, AB Science, and more.
URL:
Brochure: https://go.evvnt.com/1485150-3?pid=4832
Speakers: Alain Moussy, Co-Founder and Chief Executive Officer, AB Science, and more.
Anfragen und Anmeldung:
https://go.evvnt.com/1485150-2?pid=4832
Frau Erin Thomas
Allgemeinmedizin
Veranstalter Kontakt
83 Great Titchfield Street
W1W 6RH London
Großbritannien
83 Great Titchfield Street
W1W 6RH London
Großbritannien
"GOING INTERNATIONAL fördert den Zugang zu Aus-, Fort- und Weiterbildung, unabhängig von sozialen, geographischen und nationalen Grenzen."
